Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

2021/07/27 by José Manuel Valdivielso, José M. Valdivielso, Olga Balafa +9 · 26 citations
Medicine · #Potassium and Related Disorders #Heart Failure Treatment and Management #Electrolyte and hormonal disorders

paper · doi:10.1007/s40265-021-01555-5

Citations

• The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
• Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

Cited by

• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
• Chinese Clinical Practice Guideline for the Management of "CKD-PeriDialysis"-the Periods Prior to and in the Early-Stage of Initial Dialysis. [europepmc]
• Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review. [europepmc]
• Association Between Dietary Potassium Intake Estimated From Multiple 24-Hour Urine Collections and Serum Potassium in Patients With CKD. [europepmc]
• Hyperkalemia in pediatric chronic kidney disease. [europepmc]
• Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere ! [europepmc]
• Non-Coding RNAs and Gut Microbiota in the Pathogenesis of Cardiac Arrhythmias: The Latest Update. [europepmc]
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). [europepmc]
• Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men. [europepmc]
• A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. [europepmc]
• Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease. [europepmc]
• The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis. [europepmc]
• Artificial intelligence in chronic kidney diseases: methodology and potential applications. [europepmc]
• Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models. [europepmc]
• The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer. [europepmc]
• Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study. [europepmc]
• Guidelines for the management of hypertension in CKD patients: where do we stand in 2024? [europepmc]
• Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis. [europepmc]
• Evaluation of the Correlation between Gut Microbiota and Renal Function in Chronic Kidney Disease Patients. [europepmc]
• Mechanism of mesenchymal stem cells in treating diabetic kidney disease. [europepmc]
• In vivo electrochemical reduction-induced reconfiguration of Prussian blue for metal counterion-free potassium removal in hyperkalemia. [europepmc]
• Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden. [europepmc]
• Impact of Duration of Outpatient Sodium Zirconium Cyclosilicate Therapy on Hyperkalemia-Related Health Care Resource Utilization: A Matched Cohort Analysis. [europepmc]
• Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories. [europepmc]
• Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial. [europepmc]